trial · primary record
gemcitabine + docetaxel
Urinary Bladder Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 31 |
| Primary completion | 2027-10-19 |
| Primary endpoint | Complete response rate (CR) for treatment with intravesical gemcitabine for patients with intermediate and high-risk NMIBC |
| Registry ID | NCT05644041 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:31.725Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05644041
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.